Clinical Trials Logo

Mycoplasma Pneumonia clinical trials

View clinical trials related to Mycoplasma Pneumonia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03613636 Completed - Diagnosis Clinical Trials

Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)

myCAP
Start date: May 1, 2016
Phase:
Study type: Observational

To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and serology, in a cohort of children with community-acquired pneumonia (CAP) and controls.

NCT ID: NCT01259141 Completed - Clinical trials for Mycoplasma Pneumonia

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Start date: October 2010
Phase: N/A
Study type: Interventional

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

NCT ID: NCT00926601 Enrolling by invitation - Clinical trials for Pulmonary Tuberculosis

Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis

Start date: June 2009
Phase: N/A
Study type: Observational

Several case report showed that the co-infection of Mycoplasma pneumoniae in patients with pulmonary tuberculosis. The aim of this study is to elucidate the prevalence and its clinical significance of co-infection of Mycoplasma pneumonia in patients with newly diagnosed pulmonary tuberculosis.

NCT ID: NCT00471757 Completed - Clinical trials for Streptococcus Pneumonia

Etiology of Community Acquired Pneumonia

CAP
Start date: May 2007
Phase:
Study type: Observational

The proposed study aims to provide current information, etiology and outcome of community-acquired pneumonia (CAP), risk factors for for CAP in isolates of Streptococcus pneumoniae and Haemophilus influencae, Mycoplasma pneumoniae, chlamydia pneumoniae and Legionella. Risk factors, including patient demographics, comorbid illnesses, setting of presentation, causative organisms, antibiotic history, and resistance profiles will be assessed and outcome will be recorded.